UK govt shot in the arm for Croda vaccine facility

1 April 2022

A grant of £15.9 million ($20.9 million) has been awarded to chemical producer Croda International to increase the UK’s manufacturing capacity of specialty lipids, an essential ingredient in mRNA vaccines, the government has announced today.

This investment will enable Croda, a global market leader in the field, to significantly increase production capacity at its facility in Leek, Staffordshire.

This will also allow the firm to increase both the range and volume of lipids it is able to produce in the UK, particularly the mRNA lipid used in a number of Covid vaccines - as well as creating a number of jobs at the site.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK